AEterna Zentaris (AEZS) Lifted to “Buy” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a hold rating to a buy rating in a report released on Monday. The firm currently has $4.50 price target on the biopharmaceutical company’s stock.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Several other research firms also recently issued reports on AEZS. Maxim Group set a $2.00 price objective on shares of AEterna Zentaris and gave the company a buy rating in a research note on Thursday, December 20th. ValuEngine upgraded shares of AEterna Zentaris from a sell rating to a hold rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the company a buy rating in a research note on Thursday, December 20th. Four investment analysts have rated the stock with a buy rating, AEterna Zentaris currently has an average rating of Buy and an average target price of $3.17.

NASDAQ AEZS opened at $4.00 on Monday. AEterna Zentaris has a 1 year low of $1.12 and a 1 year high of $4.39. The firm has a market capitalization of $65.10 million, a price-to-earnings ratio of 12.38 and a beta of 1.23.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in AEterna Zentaris in the fourth quarter valued at $30,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of AEterna Zentaris during the fourth quarter worth about $66,000. Acadian Asset Management LLC boosted its stake in shares of AEterna Zentaris by 27.2% during the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 9,640 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of AEterna Zentaris during the third quarter worth about $101,000. Institutional investors own 15.29% of the company’s stock.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Newpark Resources Inc  Shares Bought by Bank of America Corp DE
Newpark Resources Inc Shares Bought by Bank of America Corp DE
Advisor Group Inc. Grows Holdings in ProShares Short 20+ Year Treasury
Advisor Group Inc. Grows Holdings in ProShares Short 20+ Year Treasury
Claybrook Capital LLC Purchases New Holdings in UnitedHealth Group Inc
Claybrook Capital LLC Purchases New Holdings in UnitedHealth Group Inc
Advisor Group Inc. Takes $34,000 Position in SPDR Gold MiniShares Trust
Advisor Group Inc. Takes $34,000 Position in SPDR Gold MiniShares Trust
Ausdal Financial Partners Inc. Cuts Stake in SPDR S&P 500 ETF Trust
Ausdal Financial Partners Inc. Cuts Stake in SPDR S&P 500 ETF Trust
Advisor Group Inc. Sells 269 Shares of Re/Max Holdings Inc
Advisor Group Inc. Sells 269 Shares of Re/Max Holdings Inc


 
© 2006-2019 Zolmax.